Does the media favor PRME or BEAM?

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 14 mentions for Beam Therapeutics and 8 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.50 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KLRA or PRME?

In the previous week, Kailera Therapeutics and Kailera Therapeutics both had 8 articles in the media. Prime Medicine's average media sentiment score of 0.85 beat Kailera Therapeutics' score of 0.43 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VERA or PRME?

In the previous week, Vera Therapeutics had 27 more articles in the media than Prime Medicine. MarketBeat recorded 35 mentions for Vera Therapeutics and 8 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.85 beat Vera Therapeutics' score of 0.56 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MOR or PRME?

Prime Medicine has a consensus price target of $7.53, indicating a potential upside of 113.05%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Prime Medicine 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Is MOR or PRME more profitable?

MorphoSys has a net margin of -226.79% compared to Prime Medicine's net margin of -4,917.55%. Prime Medicine's return on equity of -188.82% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Prime Medicine -4,917.55% -188.82% -60.97%

Do analysts recommend RGC or PRME?

Prime Medicine has a consensus price target of $7.53, indicating a potential upside of 113.05%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prime Medicine 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has preferable valuation and earnings, RGC or PRME?

Regencell Bioscience has higher earnings, but lower revenue than Prime Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Prime Medicine $4.63M 137.90 -$201.14M -$1.23 N/A

Does the media refer more to RGC or PRME?

In the previous week, Prime Medicine had 6 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for Prime Medicine and 2 mentions for Regencell Bioscience. Prime Medicine's average media sentiment score of 0.85 beat Regencell Bioscience's score of 0.58 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prime Medicine (PRME) Competitors

$3.52 -0.26 (-6.88%)

Closing price 04:00 PM Eastern

Extended Trading

$3.56 +0.04 (+1.25%)

As of 04:45 PM Eastern

Compare

PRME vs. BEAM, KLRA, VERA, MOR, and RGC

Should you buy Prime Medicine stock or one of its competitors? MarketBeat compares Prime Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prime Medicine include Beam Therapeutics (BEAM), Kailera Therapeutics (KLRA), Vera Therapeutics (VERA), MorphoSys (MOR), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

How does Prime Medicine compare to Beam Therapeutics?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	137.90	-$201.14M	-$1.23	N/A
Beam Therapeutics	$139.74M	22.94	-$79.99M	-$0.68	N/A

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 14 mentions for Beam Therapeutics and 8 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.50 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine presently has a consensus target price of $7.53, indicating a potential upside of 113.05%. Beam Therapeutics has a consensus target price of $46.85, indicating a potential upside of 50.36%. Given Prime Medicine's stronger consensus rating and higher probable upside, research analysts plainly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Prime Medicine has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Summary

Beam Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Prime Medicine (NASDAQ:PRME) are both manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, Kailera Therapeutics and Kailera Therapeutics both had 8 articles in the media. Prime Medicine's average media sentiment score of 0.85 beat Kailera Therapeutics' score of 0.43 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 114.29%. Prime Medicine has a consensus target price of $7.53, suggesting a potential upside of 113.05%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kailera Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

70.4% of Prime Medicine shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kailera Therapeutics has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Prime Medicine	$4.63M	137.90	-$201.14M	-$1.23	N/A

Kailera Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Kailera Therapeutics' return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

Kailera Therapeutics and Prime Medicine tied by winning 6 of the 12 factors compared between the two stocks.

How does Prime Medicine compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vera Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Vera Therapeutics' return on equity of -74.86% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Vera Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market.

In the previous week, Vera Therapeutics had 27 more articles in the media than Prime Medicine. MarketBeat recorded 35 mentions for Vera Therapeutics and 8 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.85 beat Vera Therapeutics' score of 0.56 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Prime Medicine	$4.63M	137.90	-$201.14M	-$1.23	N/A

Vera Therapeutics presently has a consensus target price of $84.58, suggesting a potential upside of 104.58%. Prime Medicine has a consensus target price of $7.53, suggesting a potential upside of 113.05%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Prime Medicine beats Vera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

In the previous week, Prime Medicine had 8 more articles in the media than MorphoSys. MarketBeat recorded 8 mentions for Prime Medicine and 0 mentions for MorphoSys. Prime Medicine's average media sentiment score of 0.85 beat MorphoSys' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Prime Medicine	Positive

MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

Prime Medicine has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Prime Medicine	$4.63M	137.90	-$201.14M	-$1.23	N/A

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Prime Medicine has a consensus price target of $7.53, indicating a potential upside of 113.05%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

MorphoSys has a net margin of -226.79% compared to Prime Medicine's net margin of -4,917.55%. Prime Medicine's return on equity of -188.82% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

Prime Medicine beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Prime Medicine (NASDAQ:PRME) are both manufacturing companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Regencell Bioscience has higher earnings, but lower revenue than Prime Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Prime Medicine	$4.63M	137.90	-$201.14M	-$1.23	N/A

Regencell Bioscience has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Regencell Bioscience's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Prime Medicine	-4,917.55%	-188.82%	-60.97%

In the previous week, Prime Medicine had 6 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for Prime Medicine and 2 mentions for Regencell Bioscience. Prime Medicine's average media sentiment score of 0.85 beat Regencell Bioscience's score of 0.58 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Regencell Bioscience has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market.

Prime Medicine has a consensus price target of $7.53, indicating a potential upside of 113.05%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Prime Medicine beats Regencell Bioscience on 10 of the 14 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$638.49M	$549.29M	$4.35B	$12.45B
Dividend Yield	N/A	N/A	27.48%	8.01%
P/E Ratio	-2.87	N/A	23.78	24.31
Price / Sales	137.90	70.94	101.77	96.27
Price / Cash	N/A	N/A	31.98	49.39
Price / Book	5.28	2.87	12.24	6.29
Net Income	-$201.14M	-$81.71M	$118.20M	$330.86M
7 Day Performance	-11.40%	0.34%	-2.53%	-2.33%
1 Month Performance	27.16%	22.89%	-1.86%	-0.59%
1 Year Performance	N/A	-64.01%	9.60%	19.95%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	3.1846 of 5 stars	$3.52 -6.9%	$7.53 +114.0%	N/A	$635.77M	$4.03M	N/A	N/A	News Coverage Gap Down
BEAM Beam Therapeutics	3.3897 of 5 stars	$37.92 +7.4%	$46.83 +23.5%	+54.4%	$3.63B	$139.74M	N/A	510	Gap Down
KLRA Kailera Therapeutics	4.1758 of 5 stars	$22.24 -4.5%	$42.75 +92.2%	N/A	$2.88B	N/A	N/A	145	Short Interest Increase
VERA Vera Therapeutics	3.4995 of 5 stars	$42.96 +7.1%	$80.45 +87.3%	+76.3%	$2.88B	N/A	N/A	40	Analyst Revision High Trading Volume
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, KLRA, VERA, MOR, and RGC

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to Kailera Therapeutics?

Summary

How does Prime Medicine compare to Vera Therapeutics?

Summary

How does Prime Medicine compare to MorphoSys?

Summary

How does Prime Medicine compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, KLRA, VERA, MOR, and RGC

How does Prime Medicine compare to Beam Therapeutics?

Is PRME or BEAM more profitable?

Which has stronger earnings and valuation, PRME or BEAM?

Does the media favor PRME or BEAM?

Do analysts prefer PRME or BEAM?

Do institutionals & insiders have more ownership in PRME or BEAM?

Which has more risk & volatility, PRME or BEAM?

Summary

How does Prime Medicine compare to Kailera Therapeutics?

Does the media prefer KLRA or PRME?

Do analysts prefer KLRA or PRME?

Do institutionals and insiders have more ownership in KLRA or PRME?

Which has stronger earnings and valuation, KLRA or PRME?

Is KLRA or PRME more profitable?

Summary

How does Prime Medicine compare to Vera Therapeutics?

Do institutionals and insiders have more ownership in VERA or PRME?

Is VERA or PRME more profitable?

Which has more risk and volatility, VERA or PRME?

Does the media refer more to VERA or PRME?

Which has stronger earnings and valuation, VERA or PRME?

Do analysts prefer VERA or PRME?

Summary

How does Prime Medicine compare to MorphoSys?

Does the media refer more to MOR or PRME?

Which has more volatility & risk, MOR or PRME?

Which has preferable valuation and earnings, MOR or PRME?

Do institutionals and insiders believe in MOR or PRME?

Do analysts rate MOR or PRME?

Is MOR or PRME more profitable?

Summary

How does Prime Medicine compare to Regencell Bioscience?

Which has preferable valuation and earnings, RGC or PRME?

Is RGC or PRME more profitable?

Does the media refer more to RGC or PRME?

Do insiders and institutionals have more ownership in RGC or PRME?

Which has more risk & volatility, RGC or PRME?

Do analysts recommend RGC or PRME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools